Get the Stockscreener App
4.20
10.24%
0.39
Pre-market:
4.20
Climb Bio Inc stock is traded at $4.20, with a volume of 631.51K.
It is up +10.24% in the last 24 hours and up +144.19% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$3.81
Open:
$3.84
24h Volume:
631.51K
Relative Volume:
0.49
Market Cap:
$286.37M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-1.9535
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
+5.00%
1M Performance:
+144.19%
6M Performance:
+233.33%
1Y Performance:
+100.96%
1-Day Range:
$3.83
$4.25
1-Week Range:
$3.46
$4.25
52-Week Range:
$1.05
$5.048
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
4.20 | 259.78M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | William Blair | Outperform |
| Oct-13-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
View All
Climb Bio Inc Stock (CLYM) Latest News
Climb Bio reports inducement grant under Nasdaq listing rule - MSN
Climb Bio (CLYM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Climb Bio Inc Stock Analysis and ForecastSector Performance Review & Explosive Capital Growth Plans - earlytimes.in
Setup Watch: Will SBUX stock benefit from commodity pricesPortfolio Value Summary & AI Driven Price Forecasts - moha.gov.vn
Alumis issues breach notice to Climb Bio over $3 million milestone payment - Investing.com Nigeria
Climb Bio appoints Edgar D. Charles as Chief Medical Officer - MSN
Alumis IncCo & Its Unit Issues Notice Of Material Breach & Notification Of Claim For Indemnification To Climb BioSEC Filing - TradingView — Track All Markets
Alumis issues breach notice to Climb Bio over $3 million milestone payment By Investing.com - Investing.com South Africa
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Climb Bio challenges Alumis milestone and royalty obligations - MSN
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Climb Bio files complaint against Alumis and AcelyrinSEC filing - MarketScreener
Climb Bio Challenges Alumis Milestone and Royalty Obligations - TipRanks
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks - Insider Monkey
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio's (CLYM) Budoprutug Across Clinical Tracks - Finviz
Climb Bio initiated with a buy at Freedom Capital - MSN
Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target - Investing.com Canada
Climb Bio initiated with a Buy at Freedom Capital - TipRanks
Apollo Tyres Limited Stock Poised for Technical ComebackTrading Psychology Tips & Outstanding Investment Portfolio - bollywoodhelpline.com
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Yahoo Finance
Climb Bio price target raised to $11 from $9 at HC Wainwright - MSN
Retail investors in Climb Bio, Inc. (NASDAQ:CLYM) are its biggest bettors, and their bets paid off as stock gained 15% last week - simplywall.st
Vilin Bio Med Limited Breaks Losing Streak — Is the Trend ReversingStock Split Announcements & Rapid Wealth Accumulation - bollywoodhelpline.com
AI Indicators Detect Buy Opportunity in Shree OSFM ESupport and Resistance Levels & Build a Smarter Portfolio Right Now - bollywoodhelpline.com
Candlestick Signal Suggests Reversal in Rajputana Industries LimitedTechnical Resistance Breaks & Accelerated Capital Growth - bollywoodhelpline.com
HC Wainwright Reduces Earnings Estimates for Climb Bio - MarketBeat
Can Climb Bio Inc. stock deliver sustainable ROE2025 Growth vs Value & Consistent Profit Trade Alerts - Улправда
Climb Bio Earnings Notes - Trefis
Climb Bio Inc. (CLYM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why analysts upgrade Climb Bio Inc. stockMarket Sentiment Report & Technical Pattern Based Buy Signals - DonanımHaber
Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
H.C. Wainwright raises Climb Bio stock price target to $11 on budoprutug progress - Investing.com Canada
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
HC Wainwright & Co. Raises Climb Bio (CLYM) Price Target to $11. - GuruFocus
HC Wainwright & Co. Maintains Climb Bio (CLYM) Buy Recommendation - Nasdaq
Climb Bio price target raised to $11 from $9 at H.C. Wainwright - TipRanks
Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ra Capital Management, L.P. Buys 101,462 Shares of Climb Bio (NASDAQ:CLYM) Stock - Defense World
Climb Bio Stock 7-Day Winning Spree: Stock Climbs 169% - Trefis
Climb Bio Soars Amid Strategic Move and Market Optimism - timothysykes.com
Monday’s Insider Moves: Prairie Operating Owner Leads Buying Spree By Investing.com - Investing.com South Africa
Monday’s Insider Moves: Prairie Operating Owner Leads Buying Spree - Investing.com
Climb Bio (NASDAQ:CLYM) Director Ra Capital Management, L.P. Purchases 213,099 Shares - Defense World
Climb Bio Stock Rockets 122% With 6-Day Winning Streak - Trefis
Climb bio sees $754k in purchases from RA Capital funds By Investing.com - Investing.com South Africa
Climb bio sees $754k in purchases from RA Capital funds - Investing.com Canada
Ra Capital Management, L.P. Buys 213,099 Shares of Climb Bio (NASDAQ:CLYM) Stock - MarketBeat
Insider Buying: Climb Bio (NASDAQ:CLYM) Director Buys 101,462 Shares of Stock - MarketBeat
Owner RA Capital Management LP Buys 314,561 ($754.7K) Of Climb Bio Inc [CLYM] - TradingView — Track All Markets
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):